What is Iambic Therapeutics?
AI-driven small-molecule drug discovery and development company.
- Category
- AI drug discovery
- Headquarters
- San Diego, California
- Founded
- 2019
- Employees
- Private; biotech R&D organization
- Total funding
- About $153 million disclosed
- Status
- Private
What is Iambic Therapeutics?
Iambic Therapeutics is a ai drug discovery company headquartered in San Diego, California.
Iambic uses physics-informed AI and automated drug-discovery workflows to design small-molecule therapeutics and advance internal programs. The company works with pharma partners and is building an internal oncology and immunology pipeline; customer counts are not public.
The company was founded in 2019 and remains private. Its public profile is strongest around OrbNet and NeuralPLexer, while detailed revenue figures are not publicly disclosed.
As of June 2026, the safest public read is that Iambic Therapeutics is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.
What does Iambic Therapeutics offer?
Iambic Therapeutics's public product set centers on OrbNet, NeuralPLexer, Internal pipeline.
- OrbNet· AI chemistry
- NeuralPLexer· Structure prediction
- Internal pipeline· Drug development
- Automated discovery platform· R&D
Sources:Iambic Therapeutics website
How does Iambic Therapeutics make money?
Biotech pipeline model with partnerships and future milestone economics; no software pricing is public.
Biotech pipeline model with partnerships and future milestone economics; no software pricing is public. No public product pricing; therapeutics company.
Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because Iambic Therapeutics does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.
The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.
Who leads Iambic Therapeutics?
Iambic Therapeutics is led by Tom Miller, Co-founder and CEO.
- Tom MillerCo-founder and CEOCo-founder · since 2019Former professor and computational chemistry researcher.
- Fred ManbyCo-founder and CTOCo-founderComputational chemistry scientist.
- Michael BrownChief Scientific OfficerExecutiveDrug-discovery executive guiding pipeline science.
How do you contact Iambic Therapeutics's leadership?
Public contact form; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.
Public contact form; no verified personal email pattern foundSources:Iambic Therapeutics website
How much funding has Iambic Therapeutics raised?
Iambic Therapeutics has about $153 million disclosed and is private.
2020: Seed/early — Undisclosed, led/backed by Reported venture investors. 2021: Series A — $53 million, led/backed by Lux Capital. 2023: Series B — $100 million, led/backed by Ascenta Capital and others (Valuation undisclosed).
The latest public valuation/status marker is Undisclosed. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.
Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.
How did Iambic Therapeutics get here?
Iambic Therapeutics's timeline runs from its 2019 founding through major financing and product milestones.
- 2019Founded as EntosThe company began as an AI chemistry startup.
- 2021Series AIambic raised $53 million to scale AI drug discovery.
- 2022Rebrand to IambicThe company adopted the Iambic Therapeutics name.
- 2023Series BIambic raised $100 million for platform and pipeline work.
- 2025Pipeline maturationThe company continued advancing AI-designed therapeutics.
Who are Iambic Therapeutics's competitors?
Iambic Therapeutics competes with specialized startups and larger platform companies in ai drug discovery.
Iambic Therapeutics — frequently asked questions
